Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Last updated March 14, 2022

Key Points

Key Points

  • Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
  • Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
  • Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.

Treatment

...Treatment...

...IDH-mutant Astr...

Oligodendr...

...ommendation 1.1People with oligodendrogl...

...de is a reasonable alternative to...

...1.2Within the group of people with oligo...

...Oligodendroglioma, I...

...1.3People with oligodendroglioma, IDH-mutant,...

...s a reasonable alternative to PCV when...

...Astro...

...mmendation 1.4People with astrocytoma, I...

...ommendation 1.5In astrocytoma, IDH-mutant...

...As...

....6People with astrocytoma, IDH-mutant, 1...

...Astrocytoma, IDH...

...ommendation 1.7People with astrocytoma, IDH-mu...

...Glioblastoma and Ot...

...2.1People with astrocytomas, IDH-wildtype, CNS...

...tion 2.2Concurrent temozolomide and radiati...

...ation 2.3Six months of adjuvant temozolomide sho...

...tion 2.4Alternating electric field therapy...

Recommendation 2.5Bevacizumab is NOT recommended...

...endation 2.6In people with glioblastoma, IDH-wild...

...ion 2.7In people with glioblastoma, IDH-wi...

...dation 2.8No recommendation for or against a...

...urrent glioblastoma should be referred for pa...

...2.9No recommendation for or against...

...le with diffuse midline glioma should be referre...


Table 1. Reasonable Doses and Schedules by Recommendation

...e 1. Reasonable Doses and Schedules by R...